Analyst firms · UBS · DVA

UBS DVA price target and rating history

DaVita Inc. (DVA) · Health Care

UBS rates DaVita Inc. (DVA) Buy with a $142 price target, as of its latest action on Aug 7, 2023. It has published 3 rating actions on DVA since August 2022, including 1 upgrade and 1 downgrade.

Current rating
Buy
Price target
$142
Median target, all firms
Too few
Actions on DVA
3

UBS price target on DVA

$142$108$742023202420252026
UBS price target on DVA, each point a stated target, August 2022 to August 2023.

Every UBS rating on DVA

How other firms rate DVA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
TD CowenBuy$220Aug 7, 2026
Deutsche BankBuy$220May 6, 2026

Questions about UBS and DVA

What is UBS's price target for DVA?
UBS's latest stated price target for DaVita Inc. (DVA) is $142, from its action on Aug 7, 2023.
What is UBS's rating on DVA?
UBS rates DVA Buy, a bullish rating, as of Aug 7, 2023.
When did UBS last change its view on DVA?
On Aug 7, 2023, UBS upgrades to Buy from Neutral, price target $100 to $142.

More DVA rating histories

All UBS ratingsDVA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.